Ohr Pharmaceutical's treatment for an eye condition that can lead to blindness failed to meet a key goal in a mid-stage study, sending shares down 44 percent before the opening bell Friday.
Ohr Pharmaceutical's treatment for an eye condition that can lead to blindness failed to meet a key goal in a mid-stage study, sending shares down 44 percent before the opening bell Friday.